Driehaus Capital Management’s Corcept Therapeutics CORT Stock Holding History

Driehaus Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-526,602	Closed	-$43.8M	–	422
2025 Q3	$43.8M	Buy	526,602 +45,297	+9%	+$3.28M	0.31%	104
2025 Q2	$35.3M	Buy	481,305 +221,655	+85%	+$16.1M	0.28%	119
2025 Q1	$29.7M	Buy	+259,650	New	+$15.8M	0.29%	113
2017 Q4	–	Sell	-28,515	Closed	-$550K	–	543
2017 Q3	$550K	Buy	+28,515	New	+$425K	0.02%	385
2017 Q2	–	Sell	-400,717	Closed	-$4.39M	–	555
2017 Q1	$4.39M	Buy	+400,717	New	+$3.52M	0.15%	151
2016 Q3	–	Sell	-102,657	Closed	-$561K	–	527
2016 Q2	$561K	Buy	+102,657	New	+$534K	0.02%	417
2015 Q3	–	Sell	-35,039	Closed	-$211K	–	554
2015 Q2	$211K	Buy	+35,039	New	+$215K	0.01%	491

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Driehaus Capital Management's CORT Position: Q4 2025 in Review

Driehaus Capital Management sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 526,602 shares — an estimated $43.8M sold.

Driehaus Capital Management first reported a position in CORT in Q2 2015 and held it in 7 quarters. The position peaked at $43.8M in Q3 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

Driehaus Capital Management reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
Driehaus Capital Management sold 526,602 Corcept Therapeutics shares in Q4 2025, an estimated $43.8M.
Driehaus Capital Management first reported a position in Corcept Therapeutics in Q2 2015 and held it in 7 quarters.
Driehaus Capital Management's Corcept Therapeutics position peaked at $43.8M in Q3 2025.
389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Driehaus Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.